UK markets closed

Almirall, S.A. (0O9B.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
8.15-0.01 (-0.15%)
At close: 05:57PM BST
Full screen
Previous close8.16
Bid7.98 x 0
Ask8.41 x 0
Day's range8.11 - 8.24
52-week range7.20 - 10.08
Avg. volume46,405
Market cap1.856B
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.18 (2.03%)
Ex-dividend date12 May 2023
1y target estN/A

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).